Health Care • Biotechnology: Pharmaceutical Preparations
$71.91 ▼ -1.48
(-2.02%)
MKT CAP: $482.7M • VOL: 163.1K
52W L $50 52W H $125
ROARABLE / RQD
E • 31/100
PIOTROSKI
3 / 9
MNPR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$16.7M | -$16.2M | -$8.8M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$13.7M | -$15.6M | -$8.4M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$12.2M | -$6.4M | -$7.9M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$12.2M | -$6.4M | -$7.9M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -17.4% | -45.0% | — |
| Cash & Short-Term Equivalents | $61.8M | $45.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $137.8M | $55.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MNPR.